REGN logo

REGN Cash from financing

annual CFF:

-$2.20B-$410.40M(-22.93%)
December 31, 2024

Summary

  • As of today (June 3, 2025), REGN annual cash flow from financing activities is -$2.20 billion, with the most recent change of -$410.40 million (-22.93%) on December 31, 2024.
  • During the last 3 years, REGN annual CFF has fallen by -$1.19 billion (-118.78%).
  • REGN annual CFF is now -672.68% below its all-time high of $384.25 million, reached on December 31, 2011.

Performance

REGN Cash from financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNcash flow metrics

quarterly CFF:

-$1.09B+$46.30M(+4.08%)
March 31, 2025

Summary

  • As of today (June 3, 2025), REGN quarterly cash flow from financing activities is -$1.09 billion, with the most recent change of +$46.30 million (+4.08%) on March 31, 2025.
  • Over the past year, REGN quarterly CFF has dropped by -$1.14 billion (-2412.53%).
  • REGN quarterly CFF is now -277.97% below its all-time high of $612.00 million, reached on September 30, 2020.

Performance

REGN quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNcash flow metrics

TTM CFF:

-$3.34B-$1.14B(-51.64%)
March 31, 2025

Summary

  • As of today (June 3, 2025), REGN TTM cash flow from financing activities is -$3.34 billion, with the most recent change of -$1.14 billion (-51.64%) on March 31, 2025.
  • Over the past year, REGN TTM CFF has dropped by -$1.92 billion (-134.90%).
  • REGN TTM CFF is now -968.40% below its all-time high of $384.25 million, reached on December 31, 2011.

Performance

REGN TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNcash flow metrics

Cash from financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

REGN Cash from financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-22.9%-2412.5%-134.9%
3 y3 years-118.8%-1783.5%-480.6%
5 y5 years-772.9%-424.6%-9067.0%

REGN Cash from financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-118.8%at low-1783.5%+4.1%-498.4%at low
5 y5-year-772.9%at low-278.0%+58.3%-9067.0%at low
alltimeall time-672.7%at low-278.0%+58.3%-968.4%at low

REGN Cash from financing History

DateAnnualQuarterlyTTM
Mar 2025
-
-$1.09B(-4.1%)
-$3.34B(+51.6%)
Dec 2024
-$2.20B(+22.9%)
-$1.14B(+79.1%)
-$2.20B(+45.6%)
Sep 2024
-
-$634.00M(+32.6%)
-$1.51B(+17.7%)
Jun 2024
-
-$478.10M(-1115.1%)
-$1.28B(-9.6%)
Mar 2024
-
$47.10M(-110.6%)
-$1.42B(-20.6%)
Dec 2023
-$1.79B(+77.4%)
-$446.10M(+9.5%)
-$1.79B(+12.5%)
Sep 2023
-
-$407.30M(-33.7%)
-$1.59B(-16.6%)
Jun 2023
-
-$614.20M(+90.4%)
-$1.91B(+36.7%)
Mar 2023
-
-$322.50M(+30.3%)
-$1.40B(+38.4%)
Dec 2022
-$1.01B(+0.3%)
-$247.60M(-65.8%)
-$1.01B(-39.5%)
Sep 2022
-
-$725.00M(+617.1%)
-$1.67B(+199.1%)
Jun 2022
-
-$101.10M(-256.3%)
-$557.60M(-3.0%)
Mar 2022
-
$64.70M(-107.1%)
-$574.70M(-42.9%)
Dec 2021
-$1.01B(-49.0%)
-$906.60M(-335.2%)
-$1.01B(+148.7%)
Sep 2021
-
$385.40M(-426.1%)
-$404.50M(+127.4%)
Jun 2021
-
-$118.20M(-67.7%)
-$177.90M(-93.3%)
Mar 2021
-
-$366.40M(+20.0%)
-$2.67B(+35.6%)
Dec 2020
-$1.97B(+681.6%)
-$305.30M(-149.9%)
-$1.97B(-2.0%)
Sep 2020
-
$612.00M(-123.4%)
-$2.01B(-23.7%)
Jun 2020
-
-$2.61B(-878.5%)
-$2.63B(+7136.0%)
Mar 2020
-
$335.60M(-197.1%)
-$36.40M(-85.6%)
Dec 2019
-$252.10M(+227.0%)
-$345.70M(+3042.7%)
-$252.10M(-2478.3%)
Sep 2019
-
-$11.00M(-28.1%)
$10.60M(-58.1%)
Jun 2019
-
-$15.30M(-112.8%)
$25.30M(-13.9%)
Mar 2019
-
$119.90M(-244.5%)
$29.40M(-138.1%)
Dec 2018
-$77.10M(+216.0%)
-$83.00M(-2343.2%)
-$77.10M(-62.3%)
Sep 2018
-
$3.70M(-133.0%)
-$204.63M(-5.5%)
Jun 2018
-
-$11.20M(-183.6%)
-$216.53M(+201.5%)
Mar 2018
-
$13.40M(-106.4%)
-$71.81M(+194.3%)
Dec 2017
-$24.40M(-96.5%)
-$210.53M(+2468.8%)
-$24.40M(-92.0%)
Sep 2017
-
-$8.20M(-106.1%)
-$305.65M(+13.7%)
Jun 2017
-
$133.52M(+119.6%)
-$268.78M(-38.0%)
Mar 2017
-
$60.81M(-112.4%)
-$433.50M(-38.1%)
Dec 2016
-$700.50M(+166.6%)
-$491.79M(-1815.0%)
-$700.50M(+229.3%)
Sep 2016
-
$28.68M(-191.9%)
-$212.72M(-63.8%)
Jun 2016
-
-$31.20M(-84.9%)
-$587.04M(+4.9%)
Mar 2016
-
-$206.19M(+5044.5%)
-$559.38M(+112.9%)
Dec 2015
-$262.80M(+20.2%)
-$4.01M(-98.8%)
-$262.80M(-48.6%)
Sep 2015
-
-$345.65M(+9677.9%)
-$511.44M(+218.4%)
Jun 2015
-
-$3.54M(-103.9%)
-$160.63M(-32.3%)
Mar 2015
-
$90.40M(-135.8%)
-$237.10M(+8.5%)
Dec 2014
-$218.55M(-402.7%)
-$252.66M(-4990.7%)
-$218.55M(-262.2%)
Sep 2014
-
$5.17M(-106.5%)
$134.72M(+1.2%)
Jun 2014
-
-$80.01M(-173.4%)
$133.09M(-21.5%)
Mar 2014
-
$108.95M(+8.3%)
$169.62M(+135.0%)
Dec 2013
$72.19M(-173.9%)
$100.62M(+2747.9%)
$72.19M(-171.2%)
Sep 2013
-
$3.53M(-108.1%)
-$101.44M(-5.0%)
Jun 2013
-
-$43.48M(-477.3%)
-$106.78M(+56.2%)
Mar 2013
-
$11.52M(-115.8%)
-$68.37M(-30.0%)
Dec 2012
-$97.65M(-125.4%)
-$73.01M(+3935.9%)
-$97.65M(-129.0%)
Sep 2012
-
-$1.81M(-64.4%)
$336.80M(-0.5%)
Jun 2012
-
-$5.08M(-71.4%)
$338.33M(-4.3%)
Mar 2012
-
-$17.75M(-104.9%)
$353.46M(-8.0%)
Dec 2011
$384.25M(+57.9%)
$361.44M(<-9900.0%)
$384.25M(+86.9%)
Sep 2011
-
-$279.00K(-102.8%)
$205.57M(-0.9%)
Jun 2011
-
$10.05M(-22.9%)
$207.46M(+3.7%)
Mar 2011
-
$13.04M(-92.9%)
$200.13M(-17.7%)
Dec 2010
$243.31M(+675.8%)
$182.76M(>+9900.0%)
$243.31M(+193.6%)
Sep 2010
-
$1.61M(-40.7%)
$82.88M(-0.6%)
Jun 2010
-
$2.72M(-95.2%)
$83.41M(+2.5%)
Mar 2010
-
$56.22M(+151.8%)
$81.36M(+159.4%)
Dec 2009
$31.36M(-116.3%)
$22.33M(+939.5%)
$31.36M(-129.4%)
Sep 2009
-
$2.15M(+222.0%)
-$106.68M(-0.8%)
Jun 2009
-
$667.00K(-89.3%)
-$107.51M(-43.0%)
Mar 2009
-
$6.22M(-105.4%)
-$188.54M(-2.2%)
Dec 2008
-$192.86M
-$115.72M(-8840.1%)
-$192.86M(-181.3%)
Sep 2008
-
$1.32M(-101.6%)
$237.09M(+0.4%)
DateAnnualQuarterlyTTM
Jun 2008
-
-$80.37M(-4323.1%)
$236.11M(-26.1%)
Mar 2008
-
$1.90M(-99.4%)
$319.35M(-0.0%)
Dec 2007
$319.40M(+72.3%)
$314.23M(>+9900.0%)
$319.40M(+72.4%)
Sep 2007
-
$347.00K(-87.9%)
$185.30M(-0.4%)
Jun 2007
-
$2.87M(+46.4%)
$186.02M(+1.1%)
Mar 2007
-
$1.96M(-98.9%)
$183.94M(-0.8%)
Dec 2006
$185.40M(+4443.0%)
$180.13M(>+9900.0%)
$185.40M(+2152.2%)
Sep 2006
-
$1.07M(+36.0%)
$8.23M(+13.5%)
Jun 2006
-
$787.00K(-77.0%)
$7.25M(+12.1%)
Mar 2006
-
$3.42M(+15.4%)
$6.47M(+58.5%)
Dec 2005
$4.08M(-8.1%)
$2.96M(+3187.8%)
$4.08M(+110.3%)
Sep 2005
-
$90.00K(+4400.0%)
$1.94M(+86.1%)
Jun 2005
-
$2000.00(-99.8%)
$1.04M(-23.9%)
Mar 2005
-
$1.03M(+25.8%)
$1.37M(-69.2%)
Dec 2004
$4.44M(-95.9%)
$819.00K(-201.4%)
$4.44M(-45.9%)
Sep 2004
-
-$808.00K(-345.6%)
$8.21M(-86.0%)
Jun 2004
-
$329.00K(-92.0%)
$58.54M(-8.2%)
Mar 2004
-
$4.10M(-10.6%)
$63.79M(-41.0%)
Dec 2003
$108.18M(+6178.8%)
$4.59M(-90.7%)
$108.18M(+3.8%)
Sep 2003
-
$49.52M(+788.1%)
$104.19M(+90.8%)
Jun 2003
-
$5.58M(-88.5%)
$54.62M(+11.1%)
Mar 2003
-
$48.50M(+8064.5%)
$49.16M(+2753.3%)
Dec 2002
$1.72M(-99.5%)
$594.00K(-1337.5%)
$1.72M(-99.1%)
Sep 2002
-
-$48.00K(-140.0%)
$192.41M(-0.2%)
Jun 2002
-
$120.00K(-88.6%)
$192.85M(-1.6%)
Mar 2002
-
$1.06M(-99.4%)
$196.03M(-43.9%)
Dec 2001
$349.12M(+275.9%)
$191.28M(>+9900.0%)
$349.12M(+121.4%)
Sep 2001
-
$398.00K(-87.9%)
$157.68M(-9.8%)
Jun 2001
-
$3.29M(-97.9%)
$174.84M(-28.4%)
Mar 2001
-
$154.15M(<-9900.0%)
$244.34M(+163.1%)
Dec 2000
$92.87M(>+9900.0%)
-$161.00K(-100.9%)
$92.87M(-0.4%)
Sep 2000
-
$17.55M(-75.9%)
$93.23M(+23.7%)
Jun 2000
-
$72.80M(+2621.4%)
$75.37M(+3073.6%)
Mar 2000
-
$2.67M(+1237.5%)
$2.38M(+691.7%)
Dec 1999
$300.00K(-121.4%)
$200.00K(-166.7%)
$300.00K(-250.0%)
Sep 1999
-
-$300.00K(+50.0%)
-$200.00K(0.0%)
Jun 1999
-
-$200.00K(-133.3%)
-$200.00K(-33.3%)
Mar 1999
-
$600.00K(-300.0%)
-$300.00K(-78.6%)
Dec 1998
-$1.40M(-103.6%)
-$300.00K(0.0%)
-$1.40M(-36.4%)
Sep 1998
-
-$300.00K(0.0%)
-$2.20M(-15.4%)
Jun 1998
-
-$300.00K(-40.0%)
-$2.60M(-106.5%)
Mar 1998
-
-$500.00K(-54.5%)
$39.90M(+1.3%)
Dec 1997
$39.40M(-40.6%)
-$1.10M(+57.1%)
$39.40M(-21.2%)
Sep 1997
-
-$700.00K(-101.7%)
$50.00M(+0.4%)
Jun 1997
-
$42.20M(-4320.0%)
$49.80M(-23.5%)
Mar 1997
-
-$1.00M(-110.5%)
$65.10M(-1.8%)
Dec 1996
$66.30M(+233.2%)
$9.50M(-1155.6%)
$66.30M(-15.6%)
Sep 1996
-
-$900.00K(-101.6%)
$78.60M(-0.3%)
Jun 1996
-
$57.50M(>+9900.0%)
$78.80M(+282.5%)
Mar 1996
-
$200.00K(-99.1%)
$20.60M(+3.5%)
Dec 1995
$19.90M(<-9900.0%)
$21.80M(-3214.3%)
$19.90M(-5075.0%)
Sep 1995
-
-$700.00K(0.0%)
-$400.00K(0.0%)
Jun 1995
-
-$700.00K(+40.0%)
-$400.00K(-20.0%)
Mar 1995
-
-$500.00K(-133.3%)
-$500.00K(+150.0%)
Dec 1994
-$200.00K(-100.4%)
$1.50M(-314.3%)
-$200.00K(-91.3%)
Sep 1994
-
-$700.00K(-12.5%)
-$2.30M(-104.7%)
Jun 1994
-
-$800.00K(+300.0%)
$49.40M(-1.0%)
Mar 1994
-
-$200.00K(-66.7%)
$49.90M(+0.2%)
Dec 1993
$49.80M(-6325.0%)
-$600.00K(-101.2%)
$49.80M(-0.8%)
Sep 1993
-
$51.00M(<-9900.0%)
$50.20M(-4663.6%)
Jun 1993
-
-$300.00K(0.0%)
-$1.10M(+10.0%)
Mar 1993
-
-$300.00K(+50.0%)
-$1.00M(+25.0%)
Dec 1992
-$800.00K(-100.9%)
-$200.00K(-33.3%)
-$800.00K(+33.3%)
Sep 1992
-
-$300.00K(+50.0%)
-$600.00K(+100.0%)
Jun 1992
-
-$200.00K(+100.0%)
-$300.00K(+200.0%)
Mar 1992
-
-$100.00K
-$100.00K
Dec 1991
$91.50M
-
-

FAQ

  • What is Regeneron Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual CFF year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?
  • What is Regeneron Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals TTM CFF year-on-year change?

What is Regeneron Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of REGN is -$2.20B

What is the all time high annual CFF for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual cash flow from financing activities is $384.25M

What is Regeneron Pharmaceuticals annual CFF year-on-year change?

Over the past year, REGN annual cash flow from financing activities has changed by -$410.40M (-22.93%)

What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of REGN is -$1.09B

What is the all time high quarterly CFF for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly cash flow from financing activities is $612.00M

What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, REGN quarterly cash flow from financing activities has changed by -$1.14B (-2412.53%)

What is Regeneron Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of REGN is -$3.34B

What is the all time high TTM CFF for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high TTM cash flow from financing activities is $384.25M

What is Regeneron Pharmaceuticals TTM CFF year-on-year change?

Over the past year, REGN TTM cash flow from financing activities has changed by -$1.92B (-134.90%)
On this page